Edition:
United Kingdom

Amgen Inc (AMGN.O)

AMGN.O on Nasdaq

182.48USD
3:52pm BST
Change (% chg)

$-1.64 (-0.89%)
Prev Close
$184.12
Open
$184.09
Day's High
$184.82
Day's Low
$181.29
Volume
1,032,013
Avg. Vol
2,782,235
52-wk High
$191.10
52-wk Low
$133.64

Chart for

About

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN... (more)

Overall

Beta: 1.40
Market Cap(Mil.): $135,588.20
Shares Outstanding(Mil.): 729.67
Dividend: 1.15
Yield (%): 2.48

Financials

  Industry Sector
P/E (TTM): -- 30.44 16.24
EPS (TTM): -- -- --
ROI: -- 14.17 10.90
ROE: -- 15.52 14.09

BRIEF-Amgen and Boston Children's Hospital enter into neuroscience research collaboration

* Amgen - co, Boston Children's Hospital entered into neuroscience research collaboration aimed at identifying novel pain targets

16 Oct 2017

BRIEF-FDA accepts supplemental biologics license application for Prolia

* FDA accepts supplemental biologics license application for Prolia® (denosumab) in glucocorticoid-induced osteoporosis

09 Oct 2017

BRIEF-Amgen, CytomX therapeutics announce strategic collaboration in Immuno-Oncology

* Amgen and CytomX Therapeutics announce strategic collaboration in immuno-oncology

03 Oct 2017

AbbVie, Amgen settlement sets Humira U.S. biosimilar launch for 2023

Amgen Inc has reached a settlement with AbbVie Inc that will delay the U.S. launch of Amgen's cheaper biosimilar version of AbbVie's cash cow, the blockbuster rheumatoid arthritis drug Humira, until Jan. 31, 2023, the companies said on Thursday.

28 Sep 2017

BRIEF-Amgen and AbbVie agree to settlement allowing commercialization of Amgevita

* Amgen and AbbVie agree to settlement allowing commercialization of Amgevita

28 Sep 2017

BRIEF-Amgen and Simcere announce strategic collaboration to co-develop and commercialize biosimilars in China

* Amgen and Simcere announce strategic collaboration to co-develop and commercialize biosimilars in China

26 Sep 2017

BRIEF-Amgen provides update on Hurricane Maria

* Amgen Inc - preliminary assessment is that critical manufacturing areas in facility in Juncos, Puerto Rico, not been significantly impacted by storm​

25 Sep 2017

U.S. FDA approves biosimilar version of cancer drug Avastin

The U.S. Food and Drug Administration said on Thursday it has approved Amgen Inc's biosimilar version of Roche Holding AG's cancer drug Avastin.

14 Sep 2017

RPT-U.S. FDA approves biosimilar version of cancer drug Avastin

Sept 14 The U.S. Food and Drug Administration said on Thursday it has approved Amgen Inc's biosimilar version of Roche Holding AG's cancer drug Avastin.

14 Sep 2017

BRIEF-U.S. FDA approved Amgen's Mvasi as a biosimilar to Avastin

* U.S. FDA says approved Amgen's Mvasi (bevacizumab-awwb) as a biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer

14 Sep 2017

Earnings vs. Estimates